Hillsdale Investment Management Inc. Has $2.28 Million Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)

Hillsdale Investment Management Inc. lifted its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 8.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 166,300 shares of the company’s stock after buying an additional 13,120 shares during the period. Hillsdale Investment Management Inc.’s holdings in Myriad Genetics were worth $2,280,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Atria Investments Inc grew its holdings in Myriad Genetics by 5.4% in the third quarter. Atria Investments Inc now owns 11,414 shares of the company’s stock worth $313,000 after purchasing an additional 581 shares during the period. Point72 Hong Kong Ltd acquired a new stake in shares of Myriad Genetics in the 3rd quarter valued at about $32,000. Point72 Asia Singapore Pte. Ltd. increased its position in Myriad Genetics by 43.8% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company’s stock valued at $132,000 after buying an additional 1,471 shares in the last quarter. Blue Trust Inc. raised its stake in Myriad Genetics by 14.1% during the 4th quarter. Blue Trust Inc. now owns 14,451 shares of the company’s stock worth $198,000 after buying an additional 1,788 shares during the period. Finally, Swiss National Bank boosted its holdings in Myriad Genetics by 1.0% in the fourth quarter. Swiss National Bank now owns 178,600 shares of the company’s stock worth $2,449,000 after acquiring an additional 1,800 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on MYGN. StockNews.com lowered Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, March 13th. Piper Sandler upgraded shares of Myriad Genetics from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $11.50 to $12.50 in a report on Wednesday, March 12th. UBS Group reduced their price objective on shares of Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, February 25th. Raymond James restated an “outperform” rating and issued a $19.00 target price (down previously from $27.00) on shares of Myriad Genetics in a report on Tuesday, February 25th. Finally, The Goldman Sachs Group cut their price target on Myriad Genetics from $29.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $21.89.

Myriad Genetics Price Performance

Shares of NASDAQ MYGN opened at $10.01 on Friday. The company has a market capitalization of $914.00 million, a PE ratio of -7.70 and a beta of 1.79. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The stock’s 50 day moving average price is $12.14 and its 200-day moving average price is $17.11. Myriad Genetics, Inc. has a twelve month low of $9.36 and a twelve month high of $29.30.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The business had revenue of $210.60 million during the quarter, compared to analysts’ expectations of $210.35 million. During the same period in the prior year, the firm posted ($0.12) EPS. On average, equities analysts anticipate that Myriad Genetics, Inc. will post -0.3 EPS for the current year.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.